{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:15:38Z","timestamp":1791144938069,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhongnan Hospital of Wuhan University Science, Technology, and Innovation Seed Fund","award":["CXPY2019088"],"award-info":[{"award-number":["CXPY2019088"]}]},{"name":"Zhongnan Hospital of Wuhan University Science, Technology, and Innovation Seed Fund","award":["CXPY2019088"],"award-info":[{"award-number":["CXPY2019088"]}]},{"name":"Zhongnan Hospital of Wuhan University Science, Technology, and Innovation Seed Fund","award":["CXPY2019088"],"award-info":[{"award-number":["CXPY2019088"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00432-023-04924-7","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T02:02:22Z","timestamp":1685584942000},"page":"10041-10052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["TP53 or CDKN2A\/B covariation in ALK\/RET\/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis"],"prefix":"10.1007","volume":"149","author":[{"given":"Bin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daling","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"issue":"5","key":"4924_CR1","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","volume":"24","author":"DL Aisner","year":"2018","unstructured":"Aisner DL, Sholl LM, Berry LD et al (2018) The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations\u2014the Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res 24(5):1038\u20131047. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2289","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4924_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/path.5110","volume":"246","author":"C Alidousty","year":"2018","unstructured":"Alidousty C, Baar T, Martelotto LG et al (2018) Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations. J Pathol 246(1):67\u201376. https:\/\/doi.org\/10.1002\/path.5110","journal-title":"J Pathol"},{"key":"4924_CR3","doi-asserted-by":"publisher","first-page":"11891","DOI":"10.1073\/pnas.95.20.11891","volume":"95","author":"SA Belinsky","year":"1998","unstructured":"Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG (1998) Aberrant methylation of p16 INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci 95:11891\u201311896","journal-title":"Proc Natl Acad Sci"},{"key":"4924_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SHI et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863\u2013870. https:\/\/doi.org\/10.1200\/JCO.2011.35.6345","journal-title":"J Clin Oncol"},{"issue":"17","key":"4924_CR5","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1080\/14656566.2016.1242578","volume":"11","author":"M Caccese","year":"2016","unstructured":"Caccese M, Ferrara R, Pilotto S et al (2016) Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opin Pharmacother 11(17):2253\u20132266. https:\/\/doi.org\/10.1080\/14656566.2016.1242578","journal-title":"Expert Opin Pharmacother"},{"key":"4924_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2017.08.018","volume":"114","author":"BJ Carney","year":"2017","unstructured":"Carney BJ, Rangachari D, VanderLaan PA et al (2017) De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naive lung adenocarcinoma. Lung Cancer 114:108\u2013110. https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.018","journal-title":"Lung Cancer"},{"issue":"1","key":"4924_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ijc.31893","volume":"144","author":"P Christopoulos","year":"2019","unstructured":"Christopoulos P, Kirchner M, Bozorgmehr F et al (2019) Identification of a highly lethal V3(+) TP53(+) subset in ALK(+) lung adenocarcinoma. Int J Cancer 144(1):190\u2013199. https:\/\/doi.org\/10.1002\/ijc.31893","journal-title":"Int J Cancer"},{"issue":"10","key":"4924_CR8","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/annonc\/mdy339","volume":"29","author":"DB Costa","year":"2018","unstructured":"Costa DB (2018) TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer. Ann Oncol 29(10):2028\u20132030. https:\/\/doi.org\/10.1093\/annonc\/mdy339","journal-title":"Ann Oncol"},{"key":"4924_CR9","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-21-4316","volume":"28","author":"AYB Deneka","year":"2022","unstructured":"Deneka AYB, Baca Y, Serebriiskii IG, Nicolas E, Parker MI, Xiu J, Korn WM, Demeure MJ, Wise-Draper T (2022) Association of T P53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer. Clinical Cancer Res 28:1925\u20131937","journal-title":"Clinical Cancer Res"},{"issue":"12","key":"4924_CR10","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC et al (2017) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23(12):3012\u20133024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4924_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","volume":"18","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18(7):865\u2013875. https:\/\/doi.org\/10.1634\/theoncologist.2013-0095","journal-title":"Oncologist"},{"issue":"18","key":"4924_CR12","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22(18):4585\u20134593. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3101","journal-title":"Clin Cancer Res"},{"key":"4924_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2016.10.015","volume":"102","author":"J Jiang","year":"2016","unstructured":"Jiang J, Gu Y, Liu J et al (2016) Coexistence of p16\/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs. Lung Cancer 102:101\u2013107. https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.015","journal-title":"Lung Cancer"},{"issue":"3","key":"4924_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.lungcan.2015.06.021","volume":"89","author":"SJ Klempner","year":"2015","unstructured":"Klempner SJ, Bazhenova LA, Braiteh FS et al (2015) Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer 89(3):357\u2013359. https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.021","journal-title":"Lung Cancer"},{"issue":"3","key":"4924_CR15","doi-asserted-by":"publisher","first-page":"e1108514","DOI":"10.1080\/2162402X.2015.1108514","volume":"5","author":"J Koh","year":"2016","unstructured":"Koh J, Jang JY, Keam B et al (2016) EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3. Oncoimmunology. 5(3):e1108514. https:\/\/doi.org\/10.1080\/2162402X.2015.1108514","journal-title":"Oncoimmunology."},{"issue":"10","key":"4924_CR16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","volume":"29","author":"A Kron","year":"2018","unstructured":"Kron A, Alidousty C, Scheffler M et al (2018) Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol 29(10):2068\u20132075. https:\/\/doi.org\/10.1093\/annonc\/mdy333","journal-title":"Ann Oncol"},{"issue":"5","key":"4924_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jtho.2017.01.004","volume":"12","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Ritterhouse LL, Ali SM et al (2017) ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol 12(5):872\u2013877. https:\/\/doi.org\/10.1016\/j.jtho.2017.01.004","journal-title":"J Thorac Oncol"},{"key":"4924_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2018.09.010","volume":"125","author":"SY Liu","year":"2018","unstructured":"Liu SY, Dong ZY, Wu SP et al (2018) Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer 125:86\u201392. https:\/\/doi.org\/10.1016\/j.lungcan.2018.09.010","journal-title":"Lung Cancer"},{"issue":"4","key":"4924_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","volume":"26","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zugazagoitia J, Ahmed FS et al (2020) Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res 26(4):970\u2013977. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1040","journal-title":"Clin Cancer Res"},{"key":"4924_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2021.03.022","volume":"156","author":"T Nakasuka","year":"2021","unstructured":"Nakasuka T, Ohashi K, Watanabe H et al (2021) A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1\/TP53 mutations. Lung Cancer 156:1\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2021.03.022","journal-title":"Lung Cancer"},{"key":"4924_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.28.450217","author":"B Nguyen","year":"2021","unstructured":"Nguyen B, Fong C, Luthra A et al (2021) Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. https:\/\/doi.org\/10.1101\/2021.06.28.450217","journal-title":"Cell"},{"issue":"17","key":"4924_CR22","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","volume":"21","author":"K Ota","year":"2015","unstructured":"Ota K, Azuma K, Kawahara A et al (2015) Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 21(17):4014\u20134021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4924_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","volume":"8","author":"Z Piotrowska","year":"2018","unstructured":"Piotrowska Z, Isozaki H, Lennerz JK et al (2018) Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov 8(12):1529\u20131539. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1022","journal-title":"Cancer Discov"},{"issue":"19","key":"4924_CR24","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1158\/1078-0432.CCR-18-4049","volume":"25","author":"TA Rich","year":"2019","unstructured":"Rich TA, Reckamp KL, Chae YK et al (2019) Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations. Clin Cancer Res 25(19):5832\u20135842. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4049","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4924_CR25","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","volume":"131","author":"K Rikova","year":"2007","unstructured":"Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190\u20131203. https:\/\/doi.org\/10.1016\/j.cell.2007.11.025","journal-title":"Cell"},{"issue":"21","key":"4924_CR26","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371(21):1963\u20131971. https:\/\/doi.org\/10.1056\/NEJMoa1406766","journal-title":"N Engl J Med"},{"key":"4924_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2015.11.020","volume":"55","author":"T Tokito","year":"2016","unstructured":"Tokito T, Azuma K, Kawahara A et al (2016) Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer 55:7\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.020","journal-title":"Eur J Cancer"},{"issue":"7528","key":"4924_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"key":"4924_CR29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","volume":"8","author":"ZY Xu-Monette","year":"2017","unstructured":"Xu-Monette ZY, Zhang M, Li J, Young KH (2017) PD-1\/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol 8:1597. https:\/\/doi.org\/10.3389\/fimmu.2017.01597","journal-title":"Front Immunol"},{"key":"4924_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","volume":"158","author":"SS Zhang","year":"2021","unstructured":"Zhang SS, Nagasaka M, Zhu VW, Ou SI (2021) Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer 158:126\u2013136. https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.012","journal-title":"Lung Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04924-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04924-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04924-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T09:12:27Z","timestamp":1691831547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04924-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4924"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04924-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2837365\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Weikang Shao, Ting Ma, Yanhui Chen and Qingyun Li are employees of Genecast Biotechnology Co., Ltd. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}